Medtech Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

3Q Pharma Results Preview: Novartis, Merck, Lilly, Bayer, GSK, Bristol, Amgen, Sanofi

Executive Summary

Johnson & Johnson and Roche launched the big pharma quarterly reporting season. Next up are Novartis, Lilly, Merck, Bayer, GSK, Bristol-Myers Squibb, Amgen and Sanofi. Scrip offers some key points to watch for.

Advertisement

Related Content

Lilly's Lartruvo Scores Broad FDA Approval In Orphan Sarcomas
Genentech’s Tecentriq Stakes New Claim With FDA Lung Cancer Approval
J&J Maintains Strategy For Biosimilar Remicade As Inflectra Nears
Novartis CDK4/6 Profile Boosted But Challenge To Pfizer Rival Uncertain
ESMO Preview: Opdivo Under Pressure
Novartis' Siponimod Emerges With Solid Safety, Skirts Gilenya's Heart Effects
Indication-Based Pricing Could Be Windfall For Interleukin Inhibitors
CVS Expands Formulary Exclusions In 2017, Express Scripts’ Tally Unchanged
Lilly Executes Growth Strategy As New Products Drive Sales Gains
FDA OK's Lilly's Taltz; Rival To Novartis' Cosentyx

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097467

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel